Laikai Pharmaceutical-B (02105) announced interim results, and other revenue of 25.962 million yuan, a year-on-year increase of 30.41%

According to the Zhitong Finance App, Laikai Pharmaceutical-B (02105) announced interim results for the six months ended June 30, 2026. The group obtained additional revenue of 259.62 million yuan (RMB, same below), an increase of 30.41% year on year; R&D expenses of 97 million yuan, a decrease of 7.79% year on year; loss during the period of 2,549 million yuan, a decrease of 98.03% year on year.

According to the announcement, other income increased 6.1 million yuan or 30.7% from 1.9 million yuan for the six months ended June 30, 2025 to 26 million yuan for the six months ending June 30, 2026, mainly due to an increase in interest income from bank deposits.

LAE102 is a monoclonal antibody independently developed by the company to target ActriIA. Blocking the Activin-ActRII pathway can promote muscle regeneration and fat loss, making LAE102 a promising drug candidate for weight control while retaining muscle. LAE103 is an ActRIIb selective antibody, and LAE123 is an ActRIIA/IIb dual antagonist monoclonal antibody. Both are antibodies independently developed by the company for muscle and other disease indications. The Group has established a comprehensive ActRII product portfolio to maximize the development value of targeted ActRII receptors. Currently, the company is rapidly advancing the clinical development of this combination and is actively seeking strategic partners to accelerate its overall development and commercialization process.

In addition, the Group is also actively exploring potential combination treatment opportunities between pipeline products and currently approved drugs and traditional therapies. The company's LAE002 (afuresertib) combined trial with fluviztane has shown significant clinical value in treating HR+/HER2-breast cancer patients who have previously failed after receiving standard endocrine/antiestrogenic therapy (including CDK4/6 inhibitors). There is huge and unmet medical demand in this field, and the market potential is huge. Similarly, the company's LAE002 (afuresertib) combined with LAE001 (lapiteronel) therapy also showed good treatment benefits in patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to second-generation androgen/androgen receptor (A/AR) drugs. AstraZeneca (AstraZeneca) Capivasertib (Truqap) is the world's first approved AKT inhibitor. Following initial approval for HR+/HER2- breast cancer in November 2023, the US FDA approved capivasertib (Truqap) in combination with abiraterone (abiraterone) and prednisone (prednisone) in June 2026 to treat PTEN-deficient metastatic hormone-sensitive prostate cancer (MHSPC). Such approval significantly broadens the therapeutic range of AKT inhibitors and highlights their potential to address unmet medical needs in many tumor types. The company is committed to fully unlocking the full clinical potential of pipeline products.

During the reporting period, the Group collaborated with Eli Lilly to successfully complete the LAE102 Phase I SAD study in the US. In June 2026, the Group entered into an exclusive license agreement with Vasque Bio, according to which Vasque Bio (among other rights) was granted an exclusive license within the license area to develop, produce, commercialize and otherwise develop LAE118. In 2025, the Group and Qilu Pharmaceutical entered into an exclusive licensing agreement for LAE002 (afuresertib) in China to accelerate the regulatory approval and commercialization process of LAE002 (afuresertib) and maximize its commercial value. Looking ahead, the company will continue to seek strategic partnerships with leading pharmaceutical companies to advance clinical development and commercialization of the company's drug candidate assets.

Looking ahead, the Group aims to launch IND-supported research on LAE124, a small molecule amylin (Amylin) and calcitonin double receptor agonist, in 2026. The company has also obtained IND approval from the US FDA and the Chinese CDE for LAE118 (a PI3Kα pan-mutational selective inhibitor targeting advanced solid tumors with Pik3CA mutations). With the company's good track record in successfully developing and externally licensing LAE002 (afuresertib), the company is speeding up the development of LAE118 with the aim of providing this precise therapy for cancer patients in need of novel treatment options. The company's expanding product pipeline demonstrates its commitment to bringing life-changing treatments to patients around the world.